E-7080 |
ER-203492-00 |
LENVIMA |
LENVATINIB |
KISPLYX |
E7080 |
LENVIMA® |
E 7080 |
UNII-EE083865G2 |
4-(3-CHLORO-4-(N'-CYCLOPROPYLUREIDO)PHENOXY)-7-METHOXYQUINOLINE-6-CARBOXAMIDE |
LENVATINIB MESYLATE |
4-{3-CHLORO-4-[(CYCLOPROPYLCARBAMOYL)AMINO]PHENOXY}-7-METHOXYQUINOLINE-6-CARBOXAMIDE |
chemidplus:417716-92-8 |
chembl:CHEMBL1289601 |
rxcui:1603296 |
drugbank:09078 |
pubchem.compound:9823820 |
FDA Approval | not approved |
Drug Class | Small molecule |
Drug Indications | antineoplastic agent |
FDA Approval | Renal cell carcinoma, Thyroid cancer |
Drug Class | Kinase Inhibitors |
Drug Groups | investigational |
Drug Categories | bsep/abcb11 inhibitors |
Drug Categories | cytochrome p-450 cyp1a2 inhibitors |
Drug Categories | cytochrome p-450 cyp1a2 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp2b6 inhibitors |
Drug Categories | cytochrome p-450 cyp2b6 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp2c19 inhibitors |
Drug Categories | cytochrome p-450 cyp2c19 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp2c8 inhibitors |
Drug Categories | cytochrome p-450 cyp2c8 inhibitors (moderate) |
Drug Categories | cytochrome p-450 cyp2c9 inhibitors |
Drug Categories | cytochrome p-450 cyp2c9 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp2d6 inhibitors |
Drug Categories | cytochrome p-450 cyp2d6 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp3a inducers |
Drug Categories | cytochrome p-450 cyp3a inhibitors |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 cyp3a4 inducers |
Drug Categories | cytochrome p-450 cyp3a4 inducers (weak) |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors (weak) |
Drug Categories | cytochrome p-450 enzyme inducers |
Drug Categories | cytochrome p-450 enzyme inhibitors |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | heterocyclic compounds, fused-ring |
Drug Categories | kinase inhibitor |
Drug Categories | oat1/slc22a6 inhibitors |
Drug Categories | oat3/slc22a8 inhibitors |
Drug Categories | oatp1b1/slco1b1 inhibitors |
Drug Categories | oct2 inhibitors |
Drug Categories | p-glycoprotein substrates |
Drug Categories | qtc prolonging agents |
Drug Categories | receptor tyrosine kinase inhibitors |
Drug Categories | tyrosine kinase inhibitors |
inhibitor (inhibitory) |
Notes | |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
inhibitor (inhibitory) |
Evidence Type | Actionable |
Approval Status | Preclinical |
Response Type | sensitive |
inhibitor (inhibitory) |
Trial Name | E7080 |
Novel drug target | Established target |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Trial Name | E7080 |
Novel drug target | Established target |
Notes |
inhibitor (inhibitory) |
Trial Name | E7080 |
Novel drug target | Established target |
inhibitor (inhibitory) |
Trial Name | E7080 |
Novel drug target | Established target |
n/a |
Trial Name | E7080 |
Novel drug target | Established target |
LENVATINIB | DrugBank Drug Name |
417716-92-8 | CAS Number |
Lenvima | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
LENVATINIB | Generic Name |
Drug Class | Kinase Inhibitors |
FDA Approval | Renal cell carcinoma, Thyroid cancer |
Drug Indications | antineoplastic agent |
Drug Class | Small molecule |
FDA Approval | not approved |
CHEMBL1289601 | ChEMBL Drug ID |
LENVATINIB | Primary Drug Name |
LENVATINIB | Drug Generic Name |
E7081 | Drug Synonym |
LENVATINIB | GuideToPharmacology Ligand Name |
D0R0FO | TTD Drug ID |